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significantly decreased from 6.1 ± 0.8 to 5.7 ± 0.7 cm in
BMSC, P < 0.028 while no changes occurred in the control
group from 6.7 ± 1.0 to 6.6 ± 1.1 cm, PNS. No changes
occurred in LVEDD from 7.1 ± 0.9 to 6.9 ± 0.7 cm in BMSC
and from7.6 ± 1.1 to 7.56 ± 1.1 cm in control, PNS for both.
No significant changes in LVEF occurred in control
(26 ± 6 to 27 ± 7% PNS), while a trend for improvement
occurred BMSC from 29 ± 6 to 33 ± 10%, P < 0.059. Mitral
S wave showed trend for increase in MBSC (from 4.8 ± 1.5
to 5.3 ± 1.2 cm/s P < 0.058 while no changes occurred in
control (5.2 ± 1.7 to 5.2 ± 1.5 cm/s). Mitral E wave showed
non-significant increase from 5.7 ± 2.5 to 6.3 ± 2.6 cm/s in
BMSC, non-significant decrease was noticed in control
from 7.6 ± 2.4 to 7.1 ± 2.7 cm/s, PNS for both. There was
no procedure related morbidity or mortality in the BMSC
group.
Conclusion: On top of standard and maximum toler-
ated medical treatment for chronic systolic HF, the addi-
tion of intracoronary autologous BMSC is feasible, safe
and associated with subjective and objective functional
improvement with trend towards improvement in
parameters of LV performance.
http://dx.doi:10.1016/j.jsha.2012.06.259
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Background: C-reactive protein is an easily measur-
able acute phase reactant synthesized by hepatocytes in
response to pro-inflammatory cytokines. Elevated CRP
has been identified as a strong predictor of prognosis in
healthy individuals, in patients with stable angina, in
unstable angina and in patients after acute myocardial
infarction. The prognostic significance of high sensitivity
CRP level in percutaneous coronary intervention is
unclear.
Methods: We prospectively studied 41 patients with
chronic stable angina (28 patients) and unstable angina
(13 patients) who underwent elective coronary stenting.
All patients had normal troponin level before the proce-
dure. Blood samples for hs-CRP were obtained before the
procedure, 24 h after the procedure. Patients followed up
at 1 month and after 2 years.
Results: Mean hs_CRP before the procedure in all
patients underwent PCI was 2.38 ± 2.21 lg/ml. The mean
hs_CRP 24 h post procedure was 7.43 ± 10.6 lg/ml .There
was significant difference between pre procedural hs-
CRP and 24 h post procedural (P = 0.007). At follow up
period (1 month), no major adverse cardiac events
(MACE) have occurred. However, 24 patients complain
of chest pain. There was no significant correlation
between either pre-procedural, or 24 h post procedure
hs-CRP and chest pain (r = 0.13, 0.2, respectively). At fol-
low up period (2 years), 7 cases missed; MACE has
occurred in 13 patients.
Conclusion: Mechanical disruption of atherosclerotic
plaque during elective coronary stent implantation
causes a systemic inflammatory response. Measuring of
hs-CRP either pre-procedural or post procedural in low
risk patients is not useful for predicting of either early
or late cardiovascular events.
1. Introduction:
C - reactive protein (CRP) is an acute phase reac-
tant that responds as a sensitive, though non spe-
cific marker of systemic inflammation. This
protein is synthesized by the liver in response to
stimuli from circulating inflammatory cytokines.
CRP has traditionally been used as a systemic mar-
ker of infection and tissue injury [1].
C-reactive protein has been identified as a
strong predictor of prognosis in healthy individuals
[2,3], in patients with stable angina [4–7] and unsta-
ble angina [8–13], and in patients after an acute
myocardial infarction [14,15].
Percutaneous coronary intervention (PCI) with
stent implantation is a mainstay in the manage-
ment of severe coronary artery atherosclerotic dis-
ease. Indeed, PCI currently outperforms coronary
artery bypass grafting, and the use of interven-
tional procedures is projected to increase even
more with the adoption of new-generation drug-
eluting stents [16].
Several studies have examined the prognostic
role of CRP levels after elective or emergent PCI
with a positive prognostic impact. On the other
hand, other interventional studies failed to show a
significant correlation between CRP levels and
recurrent events or re-stenosis after elective or
emergent PCI.
Increased C-reactive protein may become an
important factor in pre-procedural risk stratifica-
tion. As an independent marker for the rapid pro-
gression of atherosclerosis or the presence of an
increased risk of subsequent adverse clinical out-
come, increased C-reactive protein may identify
high-risk patients as candidates for high dose lipid
lowering therapy and treatment with ACE inhibi-
tion [17].
The aim of this study is to assess the hs-CRP
value and its prognostic significance in long term
follow up after PCI.
2. Methods:
From March 2008 to March 2009, 41 patients, 28
of them with the diagnosis of chronic stable angina
and 13 with the diagnosis of unstable angina were
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included and underwent elective PCI of native ves-
sels and admitted to cardiology department – Assi-
ut university hospitals. The diagnosis of stable
angina was established when the frequency, dura-
tion and mode of precipitation and relief of symp-
toms remain unchanged over a duration of 2
months or more. The definition of unstable angina
is an angina pectoris (or equivalent type of ische-
mic discomfort) with any 1 of the 3 following fea-
tures: (1) Rest angina (angina commencing when
the patient is at rest), (2) New-onset (less than 2
months) severe angina, and 3) Increasing angina
(increasing in intensity, duration, and/or fre-
quency) (ACC/AHA, 2007). We have excluded
patients with the following criteria : (1) known
inflammatory, neoplastic, or infectious disease. (2)
Treatment with steroids, immunosuppressive
drugs, or non steroidal anti-inflammatory drugs
except for low-dose aspirin. (3) Angiography with
or without PCI within one month. (4) Myocardial
infarction within previous month. (5) Elevated tro-
ponin before procedure. (6) Patients with left ven-
tricular systolic dysfunction (EF < 50%). (7)
Diabetes mellitus.
3. Coronary angiography and PCI:
In all patients, 300 mg of clopidogrel were loaded
before the procedure. An intravenous bolus of
unfractionated heparin was given during the proce-
dure according to ACT level. PCI was performed
from the femoral artery approach with standard
techniques. We used bare metal stents in all
patients. The intervention was considered success-
ful when the stenosis was dilated less than 20%
residual narrowing. All the patients involved in
the study had undergone successful procedures.
After the procedure, the patients received 75 mg
clopidogrel for at least 3 months and aspirin indef-
initely. Statin, ACE Inhibitor (Angiotensin Convert-
ing Enzyme Inhibitors), and B.B. (Beta Blocker)
were prescribed according to the physician’s
discretion.
4. Laboratory assays:
The venous blood samples were obtained before
the procedure and 24 h after the procedure for hs-
CRP and troponin I determination. The blood sam-
ples were placed into plain tubes without additives.
The samples were centrifuged within 2 h and
stored at 20 C until the cytokinase assay were
performed. CRP concentration was analyzed in
serum by high sensitive method using Accu Bind
Elisa Microwells R (Monobind, USA). Troponin I
was measured using Accu Bind Elisa MicrowellsR
(Monobind, USA).
5. End point and follow up:
The end point was defined as the occurrence of
MACE (major adverse cardiac events) including
cardiac death, non fatal myocardial infarction,
unstable angina, and any coronary repeated revas-
cularization either surgery or PCI at 1 month and
after.
Follow up was obtained through telephone con-
tact with patients also personal interview.
6. Statistical analysis:
Quantitative variables were represented by
mean ± standard deviation (SD). Qualitative vari-
ables were represented by frequencies (numbers
and percentages). Paired and unpaired Student t-
test was used. Correlation coefficient (r) was used.
All analysis was performed with SPSS 10.0.
7. Results:
The clinical characteristics of the population of
the study are presented in Table 1. Mean age was
53.7, SD ± 8.85. All patients in unstable angina
group were male. Table 2 shows mean hs-CRP
before procedure, 24 h post procedure and 1 month
after procedure in patient underwent PCI (stable
and unstable angina). The mean of hs-CRP before
the procedure in unstable angina patients was
higher than in stable angina patients with a mean
difference of 2.07 which is statistically significant
(P = 0.023). As shown in Table 2, all the patients
underwent PCI, there was significant difference
between the pre-procedural hs-CRP and the 24 h
post procedure (P = 0.007) and there was highly sig-
nificant difference between the pre-procedural hs-
CRP and the 1 month post procedural value
(P = 0.000). In stable angina; there was significant
difference between pre and post procedural hs-
CRP (P = 0.008) and significant difference between
Pre-procedural hs-CRP and 1 month post proce-
dure (P = 0.001). In unstable angina; hs-CRP was
elevated 24 h post procedure but this elevation
was statistically not significant (P value = 0.225),
but there was significant difference between pre-
procedural hs-CRP and 1 month post procedure
(P = 0.025). Procedural complications are presented
in Table 3. During the follow up period (1 month);
no MACE has occurred. However, 24 patients
(58.5%) complained of chest pain. There were no
significant correlation between either pre –proce-
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dural or 24 h after procedure hs-CRP and the
occurrence of chest pain (r = 0.13, 0.2, respectively).
At long term follow up: 7 cases were lost. One case
(2.4%) died from cardiovascular cause. 12 cases
(29.3%) were complained from chest pain and
admitted to CCU. 7 cases (17.1%) underwent revas-
cularization 5 patients of them underwent PCI and
2 patients underwent CABG. There was a weak cor-
relation between the level of the pre-procedural hs-
CRP and occurrence of MACE (r = 0.22, P = 0.2) and
no correlation between post procedural hs-CRP
and occurrence of MACE. There was significant
relation between patients who complained of chest
pain at 1 month of follow up and occurrence of
MACE (P = 0.054). There was no significant differ-
ence in the level of pre-procedural hs-CRP or level
of 24 h post procedural hs-CRP between patients
who develop MACE versus those who did not(
mean pre-procedural CRP in patients with MACE
was 3.58 and who did not 2.33 with a mean differ-
ence of 1.25 which was statistically not significant
(P = 0.24) and mean post procedural hs-CRP in
patients who developed MACE was 9.32 and who
did not was 5.41 with a mean difference of 3.90
which was also statistically not significant (P = 0.36).
8. Discussion:
Ramadan et al. (2006) has shown that the mechan-
ical compression produced by balloon inflation and
stent deployment causes CRP release from the ath-
eroma plaque [18].
In our study, we found significant elevation of
hs-CRP 24 h after the procedure in all patients
underwent PCI, Goldberg et al. (2003) also found sig-
nificant increase in CRP at 24 h and 48 h compared
with baseline in patients with CSA [19]. This eleva-
tion indicate 3 possible contributing mechanisms
for the observed rise in inflammatory markers after
PCI: (1) the trauma associated with the diagnostic
part of the procedure; (2) the mechanical injury to
vessel wall by balloon inflation and stent implanta-
tion is known to induce an inflammatory reaction in
the vessel wall [20,21]; and (3) low-grade myocar-
dial necrosis after PCI can cause an inflammatory
response [22]. Almagor et al. (2002) found significant
elevation of hs-CRP 20 h post PCI in 12 patients
with stable coronary disease (P < 0.002) and 12
patients with non ST elevation myocardial infarc-
tion (NSTEMI) (P < 0.004) [23]. In our study, we
observed elevation of hs-CRP 24 h post procedure
level in unstable group. However the difference in
the magnitude of CRP level did not reach statistical
significance P = 0.225, this may due to that in our
study it involved only unstable angina patients
while in the other study it involved patients with
NSTEMI in addition.
Data regarding the value of pre-procedural hs-
CRP level and further cardiovascular events are
confusing. Several studies have examined the prog-
nostic role of CRP levels after elective or emergent
PCI with a positive prognostic impact. Buffon et al.
demonstrated that pre-procedural CRP is a power-
ful predictor of both early and late outcome during
follow up in 52 patients with diagnosis of stable
angina and 59 patients with diagnosis of unstable
angina underwent single vessel PCI [24]. Fournier
et al. examined whether hs-CRP level after 1 month
of bare metal stent implantation. The 12- month
event free survival rate was greater when hs-CRP
level was > or =2.5 mg/l. They concluded that mea-
suring of hs-CRP level 30 days after stenting may
be useful for predicting late cardiovascular events
[25]. Kyeong et al. (2009) studied 381 patients with
acute coronary syndrome who underwent elective
PCI and were followed up for 1 year, and they con-
cluded that post procedural hs_CRP elevation
>3 mg/L was associated with higher incidence of
MACE [26]. The patients enrolled in that study
had higher incidence of M.I., complex lesions
(ACC/AHA type B2/C lesion) in addition to multi
vessel stenting in which these criteria of patients
were excluded from our study. Chew et al. (2001)
studied 272 patients who underwent PCI and were
presented with NYHA class III-IV, with prior PCI,
CABG, or included patients with complex lesions
and saphenous vein graft intervention [27]. They
concluded that the elevated baseline CRP is inde-
pendently predictive of early (30 days) adverse
out come after PCI, On the other hand, other
interventional studies failed to show a significant
correlation between hs-CRP and recurrent events
or re-stenosis after elective or emergent PCI. The
GENERATION study found no association between
increased pre-procedural hs-CRP and instent re-
stenosis [28]. Rittersma et al. also could not found
any association or trend between CRP concentra-
tion and angiographic re-stenosis in 345 patients
underwent non urgent PCI who underwent clinical
angiographic follow up at 6–10 months [29] .The
patients enrolled in this study were low risk as
9% were diabetic and 3% underwent CABG. In
our study, we exclude diabetic patients and
patients underwent CABG.
The limitation of this study was the relatively
small sample size. We recommend a further study
with wide inclusion criteria of patients and large
numbers of patients.
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9. Conclusion:
Mechanical disruption of atherosclerotic plaque
during elective coronary stent implantation causes
a systemic inflammatory response. Measuring of
hs-CRP either pre-procedural or post procedural
in low risk patients is not useful for predicting of
either early or late cardiovascular events.
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